Sera Prognostics Appoints Former Myriad Genetics CEO Mark Capone to Board
SERA sits 17% above its 52-week low of $1.56.
Summary
Sera Prognostics has appointed Mark Capone, former CEO of Myriad Genetics, to its Board of Directors, bringing extensive experience in molecular diagnostics and commercial scaling.
Key Events · Executive and Board Changes · SERA
-
New Director Appointment
Mark Capone, a veteran healthcare executive and former CEO of Myriad Genetics, was appointed as a Class II director, effective July 1, 2026. He will also serve on the Compensation Committee.
-
Strengthened Board Expertise
Mr. Capone brings over 40 years of experience in molecular diagnostics, genetics, biotechnology, and medical devices, with a proven track record of transforming and growing companies, including scaling Myriad Genetics from $14M to $850M in revenue.
-
Director Compensation
Mr. Capone will receive an initial equity award with a grant date fair value of $167,072 (or 150,000 option equivalents) and annual equity awards of $88,359 (or 75,000 option equivalents), along with cash retainers for his service.
Analysis · SERA · Industrial Applications And Services
The appointment of Mark Capone, a seasoned healthcare executive with a strong track record of scaling molecular diagnostics companies, is a significant positive development for Sera Prognostics. His extensive experience in commercialization, reimbursement, and strategic growth is highly relevant as the company aims to expand adoption of its PreTRM® test and navigate its financial challenges. This strengthens the board's strategic capabilities at a critical juncture for the company.
At the time of this filing, SERA was trading at $1.82 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $71.3M. The 52-week trading range was $1.56 to $3.95. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.